Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands

Nat Med. 2020 Sep;26(9):1405-1410. doi: 10.1038/s41591-020-0997-y. Epub 2020 Jul 16.

Abstract

In late December 2019, a cluster of cases of pneumonia of unknown etiology were reported linked to a market in Wuhan, China1. The causative agent was identified as the species Severe acute respiratory syndrome-related coronavirus and was named SARS-CoV-2 (ref. 2). By 16 April the virus had spread to 185 different countries, infected over 2,000,000 people and resulted in over 130,000 deaths3. In the Netherlands, the first case of SARS-CoV-2 was notified on 27 February. The outbreak started with several different introductory events from Italy, Austria, Germany and France followed by local amplification in, and later also outside, the south of the Netherlands. The combination of near to real-time whole-genome sequence analysis and epidemiology resulted in reliable assessments of the extent of SARS-CoV-2 transmission in the community, facilitating early decision-making to control local transmission of SARS-CoV-2 in the Netherlands. We demonstrate how these data were generated and analyzed, and how SARS-CoV-2 whole-genome sequencing, in combination with epidemiological data, was used to inform public health decision-making in the Netherlands.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus / genetics*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Clinical Decision-Making
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / genetics*
  • Coronavirus Infections / pathology
  • Coronavirus Infections / virology
  • Genome, Viral / genetics*
  • Humans
  • Netherlands / epidemiology
  • Pandemics*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / genetics*
  • Pneumonia, Viral / pathology
  • Pneumonia, Viral / virology
  • Public Health
  • SARS-CoV-2
  • Whole Genome Sequencing